What guidelines and real-world practice say Despite the lack of direct trials, major guidelines support: Using the lowest effective dose Shared decision-making Individualised plans In real-world practice, many clinicians: Use a maintenance phase Reduce dose gradually Monitor appetite, weight stability, and wellbeing Adjust based on how the person feels, not just the scales This approach is not because we have perfect data, but because it aligns with physiology, patient experience, and common sense
Expect prior authorization requests
The most commonly observed include: Gastrointestinal issues such as nausea, vomiting, or diarrhea Injection site reactions (pain, redness, or itching) Hypoglycemia (low blood sugar) , especially when combined with insulin or sulfonylureas Increased heart rate in some individuals Rare allergic reactions Summary GIP/GLP-1 is a synthetic peptide analog studied in preclinical models for its interaction with GIP and GLP-1 receptors, which are central to metabolic and hormonal signaling pathways
Highly recommend!John SimoneMay 19, 2025I have had a long journey with myself wellness and their staff